Prenatal in Biological Technology

SEQUENOM Announces Launch of MassARRAY Compact 96 System

... is developing a comprehensive portfolio of prenatal test methods by combining the versatility of the ... medicine, and the Company's development of prenatal test methods and tests for oncology, infectious ... particularly new technologies such as noninvasive prenatal and other diagnostics and laboratory developed ...

Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development

... suited to lead our efforts to bring non-invasive prenatal diagnostic tests to the market," said Lissa ... exclusively on the development of non-invasive prenatal tests to determine genetic abnormalities using ... an active role in the rapidly evolving field of prenatal diagnostics." The Artemis Advantage ...

Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University

... dedicated to the development of non-invasive prenatal diagnostic tests, today announced that it has ... University to develop cell-free fetal DNA prenatal diagnostic tests based on pioneering research ... will allow the company to develop a non-invasive prenatal blood test that accurately predicts chromosomal ...

Martek Announces Third Quarter 2008 Financial Results

... Supplement Products -- Spectrum Organics' prenatal DHA for Pregnant and Nursing Mothers, Toddler ... (United States) -- Walmark's Pregnium prenatal supplement with life'sDHA(TM) (Czech ... in the United States) -- CVS Corporation's DHA prenatal Supplement with life'sDHA(TM) (United States) ...

Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic

... at the 14th International Conference on prenatal Diagnosis and Therapy (ISPD) in Vancouver, BC, will highlight Biocept's I.D.Rh(D) prenatal Diagnostic. I.D.Rh(D) is the first in a series of noninvasive prenatal diagnostic tests that can be performed with a ...

Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3

... event "Sequenom: The Future of Noninvasive prenatal Diagnostics." Details of the event are as ... What: Sequenom: The Future of Noninvasive prenatal Diagnostics When: Tuesday, June 3, 2008 at ... Inc. "Sequenom's SEQureDx: A noninvasive prenatal diagnostic test for Down syndrome. Technical ...

KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis

... net revenues up 17.2% year-to-date -- prenatal line capturing over 20.7% for fiscal year 2008 ... of the intra-vaginal prescription cream market. prenatal Line of Products: Ther-Rx prenatal vitamins comprised more than 40.5% of the ...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

... the diagnostics front, SEQUENOM is developing a comprehensive portfolio of prenatal test methods by combining the versatility of the MassARRAY system with the ... new technologies such as genetic analysis platforms, noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the ...

SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30

... translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular ... property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms. ...

Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics

... translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular ... property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms. ...

Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

... significantly reduce morbidity as well mortality rates. The market for prenatal and new-born genetic testing market in the US is estimated at US$622 ... is further analyzed by the following segments - Pharmacogenomic Testing, prenatal and Newborn Genetic Testing, and Predictive Medicine. For more details ...

Biocept Launches Noninvasive Prenatal Rh(D) Diagnostic at Annual ACOG Scientific Meeting

... I.D.Rh(D) test marks the beginning of a new era in definitive noninvasive prenatal testing," said Joe Leigh Simpson, M.D., Executive Associate Dean for ... patients who require it." "The test is the first of several noninvasive prenatal diagnostics developed by Biocept," Cotter said. "It is based on the I.D. ...

Data show a decline in cystic fibrosis since introduction of prenatal carrier screening

... the researchers compared two four-year periods: 1999 to 2002, just before prenatal CF carrier screening came into wide practice, and 2003 to 2006. The ... gradual implementation of the recommendation to offer preconception and prenatal screening in order to identify carriers of CF might have yielded a ...

Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24

... and agricultural applications, molecular medicine, and non-invasive prenatal testing. The Company's proprietary MassARRAY(R) system is a high- ... property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms. ...

Xanodyne Announces New Executive Team Members

... focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's ...

ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products

... including single cells, formalin-fixed tissue and plasma. Rubicon sells licenses and kits to the clinical markets, including pre-implantation and prenatal testing, cancer testing, and diagnostic manufacturing. For more information and to contact Rubicon, please visit http://www.rubicongenomics.com ....

KV Pharmaceutical Enters Into Consent Decree With FDA

... with FDA's current good manufacturing practices (CGMP) regulations. KV has also agreed that it will not distribute certain products, including its prenatal vitamins and hematinic products, until the products are approved by FDA's ANDA or NDA processes. "We have been working diligently with the FDA ...

Bert W. O'Malley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovo's Scientific Advisory Board

... for all future regulatory studies of the impact of estrogen and progesterone on implantation of a fertilized egg, pregnancy maintenance, and prenatal embryonic development, and for the hormone mediated embryonic and pubertal growth of breast, uterine, ovarian, prostate, and brain tissues under ...

Genzyme Reports Strong Second-Quarter Growth

... for the Genetics business increased 7 percent to $78.5 million from $73.7 million. This growth was driven in part by the continuing demand for prenatal screening for genetic conditions. Additionally, Genzyme experienced increased demand for its KRAS mutation testing for colorectal cancer, as recent ...

KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business

... aware of litigation filed by a smaller generic drug company, Lannett Company, Inc., challenging the patent rights associated with PrimaCare ONE(R), a prenatal vitamin product marketed by KV's Ther-Rx branded pharmaceutical business unit. KV has not yet been served in the lawsuit. "We are reviewing the ...

Genetic Testing for All: QTrait Offers Industry's Least Expensive, Most Secure DNA Tests With TRUSTe Certification

... gluten sensitivity. -- Parents evaluate their child's potential susceptibility to smoking, alcohol or drug addictions. -- Women determine prenatal risks such as preeclampsia or preterm birth. -- Athletes evaluate performance genes that process oxygen levels in blood; and aptitude for ...

Genzyme Reports Strong First-Quarter Growth

... and infrastructure to strengthen the competitive advantages the business has created. Genzyme Genetics recently launched carrier and prenatal diagnostic testing for spinal muscular atrophy, the most common inherited cause of infant mortality. These tests are expected to support ...

Synchrotron radiation illuminates how babies' protective bubble bursts

... the University of Reading, School of Pharmacy have developed an important new technique to study one of the most common causes of premature birth and prenatal mortality. The findings are published in the November 7 issue of the online, open-access journal PLoS ONE. Dr Che Connon, a Research Councils UK ...

GE introduces compact ultrasound system for women

... mobile imaging services - to offer 4D imaging as the standard of care for prenatal women. GE Healthcare learned of a need for more specialized, ... decisions. Dr. John Hobbins, chief of obstetrics and director of the prenatal Diagnosis and Genetics Center at the University of Colorado Health Science ...

The use of the Mastercycler gradient for single-cell PCR and preimplantation diagnosis

... Preimplantation diagnosis (PGD) is a very early form of prenatal diagnosis: embryos obtained in vitro from couples at risk of ... 68, 799-808. Clemens, P.R., et al. (1991) Carrier detection and prenatal diagnosis in Duchenne and Becker Muscular Dystrophy families, ...

Armed Forces Institute of Pathology Adopts Third Wave's Invader Screen

... (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) issued recommendations calling for all couples seeking preconception or prenatal care to be screened for 25 mutations in the CF gene. "We strive to employ cutting-edge technology for all of our genetic testing, particularly for ...

Third Wave Broadens Market, Releases Genetic Technology to Early Adopters

... important extension of the Invader technology, Madison-based Third Wave also announced it is providing Invader analyte-specific reagents (ASRs) for prenatal chromosomal analysis to the University of California, Los Angeles, Calif. and other leading institutions under an early adopter program. Customers in ...

Wisconsin-based Third Wave reports increased revenue for 2003, fourth quarter

... for high-volume customers, launch a HCV genotyping assay, establish clinical trials program for an HCV viral load prototype assay, release a prenatal chromosomal analysis product, release a HPV detection product and introduce various CYP450 products that are designed to better identify drug ...